Pharmaceutical-Contract-Development-and-Manufacturing-Market
In addition, the growing demand for cell and gene therapies and personalized medicines and growth in the High-potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) markets are expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market. However, the lack of skilled professionals and the introduction of serialization are some of the challenges for the growth of this market.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
Pharmaceutical Contract Development and Manufacturing Market Worth $226.35 Billion by 2029
Pharmaceutical Contract Development and Manufacturing Market worth $226.35 Billion by 2029 Pharmaceutical Contract Development & Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Global Forecast to 2029 According to this latest publication from Meticulous Research , the Pharmaceutical Contract Development & Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 2029 to reach $226.35 billion by 2029. The growth of the pharmaceutical contract development and manufacturing market is attributed to factors such as complex manufacturing requirements of the pharmaceutical industry, manufacturers growing inclination towards the use of cutting-edge technologies, patent expiration, increasing investments in pharmaceutical R&D, the rising demand for generic medicines and biologics, and the outbreak of the COVID-19 pandemic. To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/pharmaceutical-contract-development-and- manufacturing-market-5171 In addition, the growing demand for cell and gene therapies and personalized medicines and growth in the High-potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) markets are expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market. However, the lack of skilled professionals and the introduction of serialization are some of the challenges for the growth of this market. Pharmaceutical Contract Development and Manufacturing Market: Future Outlook The pharmaceutical contract development and manufacturing market is segmented based on Service {Manufacturing [API, FDF (Parenteral, Injectable, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing}, End User [Large Pharma, Generic] and Geography. The study also evaluates industry competitors and analyzes their market shares at the global and regional levels. Page 1 of 3 Meticulous Research| sales@meticulousresearch.com
Pharmaceutical Contract Development and Manufacturing Market worth $226.35 Billion by 2029 Based on service, in 2022, the pharmaceutical manufacturing services segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. The large share of this segment is attributed to factors such as the use of advanced technologies and skills for pharmaceutical manufacturing, the growing need to reduce manufacturing costs, the need for high-quality bulk manufacturing, and the increasing demand for generic drugs. Download Sample Copy Here: https://www.meticulousresearch.com/download-sample- report/cp_id=5171 Based on end user, in 2022, the large pharmaceutical companies segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. The large share of this segment is attributed to factors such as the rising incidence and prevalence of various diseases resulting in the increased demand for effective medicines and biopharmaceutical products, the growing need for state-of-the-art production processes and technologies, and the increasing costs of clinical trials and early development studies, leading to increased collaborations between pharmaceutical companies and contract manufacturers. Geographic Review: This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain and RoE), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America (Brazil, Mexico, RoLATAM), and the Middle East & Africa. In 2022, North America is expected to account for the largest share of the pharmaceutical contract development and manufacturing market, followed by Europe and Asia-Pacific. However, Asia- Pacific is slated to register the highest CAGR during the forecast period. The high market growth in Asia-Pacific is driven by factors such as increasing government focus on the pharmaceutical sector, growth of the region s manufacturing sector, and the rising incidence & prevalence of chronic illnesses. In addition, rising health awareness and treatment availability, low cost of manufacturing, and increased outsourcing of clinical activities are estimated to contribute to the growth of this regional market during the forecast period. Customize My Report:https://www.meticulousresearch.com/request- customization/cp_id=5171 Key Players: The key players operating in the pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GmbH (Germany) Piramal Enterprises Limited (India), Almac Group (U.K.), Cambrex Corporation (U.S.), Samsung Biologics Co., Ltd (South Korea), Siegfried Holding AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), Aenova Group (Germany), C.H. Boehringer Sohn AG & Co. KG (Germany), by Fareva SA Page 2 of 3 Meticulous Research| sales@meticulousresearch.com
Pharmaceutical Contract Development and Manufacturing Market worth $226.35 Billion by 2029 (Luxembourg), Fabbrica Italiana Sintetici S.p.A. (Italy), WuXi Biologics (Cayman) Inc. (China), and Aurobindo Pharma Ltd. (India). Buy Now:https://www.meticulousresearch.com/Checkout/67156803 Key Questions Answered in the Report- Which are the high-growth market segments in terms of service, end user, and region/country? What was the historical market size for pharmaceutical contract development and manufacturing across the globe? What are the market forecasts and estimates for 2022 2029? What are the major drivers, challenges, opportunities, and trends in the global pharmaceutical contract development and manufacturing market? Who are the major players in the global pharmaceutical contract development and manufacturing market? How is the competitive landscape, and who are the market leaders in the global pharmaceutical contract development and manufacturing market? What are the recent developments in the global pharmaceutical contract development and manufacturing market? What are the different strategies adopted by the major players in the global pharmaceutical contract development and manufacturing market? What are the geographical trends and high growth regions/countries? Contact Us: Meticulous Research Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research Page 3 of 3 Meticulous Research| sales@meticulousresearch.com
